Search by Drug Name or NDC
NDC 75834-0294-01 Erythromycin Ethylsuccinate 400 mg/5mL Details
Erythromycin Ethylsuccinate 400 mg/5mL
Erythromycin Ethylsuccinate is a ORAL SUSPENSION in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Nivagen Pharmaceuticals, Inc.. The primary component is ERYTHROMYCIN ETHYLSUCCINATE.
MedlinePlus Drug Summary
Erythromycin is used to treat certain infections caused by bacteria, such as infections of the respiratory tract, including bronchitis, pneumonia, Legionnaires' disease (a type of lung infection), and pertussis (whooping cough; a serious infection that can cause severe coughing); diphtheria (a serious infection in the throat); sexually transmitted diseases (STD), including syphilis; and ear, intestine, gynecological, urinary tract, and skin infections. It also is used to prevent recurrent rheumatic fever. Erythromycin is in a class of medications called macrolide antibiotics. It works by stopping the growth of bacteria. Antibiotics such as erythromycin will not work for colds, flu, or other viral infections. Taking antibiotics when they are not needed increases your risk of getting an infection later that resists antibiotic treatment.
Related Packages: 75834-0294-01Last Updated: 05/26/2024
MedLinePlus Full Drug Details: Erythromycin
The combination of erythromycin and sulfisoxazole (a sulfa drug) is used to treat certain ear infections caused by bacteria. It usually is used in children. This medication is sometimes prescribed for other uses; ask your doctor or pharmacist for more information.
Related Packages: 75834-0294-01Last Updated: 05/26/2024
MedLinePlus Full Drug Details: Erythromycin and Sulfisoxazole
Product Information
| NDC | 75834-0294 |
|---|---|
| Product ID | 75834-294_46f74c4f-10fc-44cf-aec4-d113f49149bc |
| Associated GPIs | |
| GCN Sequence Number | 021206 |
| GCN Sequence Number Description | erythromycin ethylsuccinate SUSP RECON 400 MG/5ML ORAL |
| HIC3 | W1D |
| HIC3 Description | MACROLIDE ANTIBIOTICS |
| GCN | 40524 |
| HICL Sequence Number | 004018 |
| HICL Sequence Number Description | ERYTHROMYCIN ETHYLSUCCINATE |
| Brand/Generic | Generic |
| Proprietary Name | Erythromycin Ethylsuccinate |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | Erythromycin Ethylsuccinate |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | SUSPENSION |
| Route | ORAL |
| Active Ingredient Strength | 400 |
| Active Ingredient Units | mg/5mL |
| Substance Name | ERYTHROMYCIN ETHYLSUCCINATE |
| Labeler Name | Nivagen Pharmaceuticals, Inc. |
| Pharmaceutical Class | Decreased Sebaceous Gland Activity [PE], Macrolide Antimicrobial [EPC], Macrolide [EPC], Macrolides [CS] |
| DEA Schedule | n/a |
| Marketing Category | ANDA |
| Application Number | ANDA216212 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 75834-0294-01 (75834029401)
| NDC Package Code | 75834-294-01 |
|---|---|
| Billing NDC | 75834029401 |
| Package | 100 mL in 1 BOTTLE (75834-294-01) |
| Marketing Start Date | 2023-02-01 |
| NDC Exclude Flag | N |
| Pricing Information | |
| Price Per Unit | 2.68753 |
| Pricing Unit | ML |
| Effective Date | 2023-05-10 |
| NDC Description | ERYTHROMYCIN 400 MG/5 ML SUSP |
| Pharmacy Type Indicator | C/I |
| OTC | N |
| Explanation Code | 4, 5 |
| Classification for Rate Setting | G |
| As of Date | 2024-02-21 |